Table 4 5ARI users stratified by duration of 5ARI use
From: 5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
Duration of 5ARI use | MRI findings | Prostate cancer detected | No prostate cancer detected | Clinically significant cancer detected | No clinically significant cancer | |||
|---|---|---|---|---|---|---|---|---|
PIRADS 0–2 | PIRADS 3 | PIRADS 4 | PIRADS 5 | |||||
Less than 6 months (n = 16) | 0 | 8 (50%) | 7 (43.8%) | 1 (6.2%) | 5 (31.3%) | 11 (68.7%) | 2 (12.5%) | 14 (87.5%) |
6 months to 1 year (n = 8) | 1 (12.5%) | 4 (50%) | 3 (37.5%) | 0 | 2 (25%) | 6 (75%) | 0 | 8 (100%) |
More than 1 year (n = 27) | 2 (7.41%) | 10 (37.0%) | 9 (33.3%) | 6 (22.2%) | 17 (63.0%) | 10 (27.0%) | 14 (51.9%) | 13 (48.1%) |